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Mu-opioid receptorNeuronal voltage-gated calcium channels generate rapid, transient intracellular calcium signals in response to
membrane depolarization. Neuronal CaV channels regulate a range of cellular functions and are implicated in a va-
riety of neurological and psychiatric diseases including epilepsy, Parkinson's disease, chronic pain, schizophrenia,
and bipolar disorder. Eachmammalian Cacna1 genehas the potential to generate tens to thousands of CaV channels
by alternative pre-mRNA splicing, a process that adds ﬁne granulation to the pool of CaV channel structures and
functions. The precise composition of CaV channel splice isoform mRNAs expressed in each cell are controlled by
cell-speciﬁc splicing factors. The activity of splicing factors are in turn regulated by molecules that encode various
cellular features, including cell-type, activity, metabolic states, developmental state, and other factors. The cellular
and behavioral consequences of individual sites of CaV splice isoforms are being elucidated, as are the cell-speciﬁc
splicing factors that control splice isoform selection. Altered patterns of alternative splicing of CaV pre-mRNAs can
alter behavior in subtle but measurable ways, with the potential to inﬂuence drug efﬁcacy and disease severity.
This article is part of a Special Issue entitled: Calcium channels.
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Voltage-gated calcium channel (CaV) currents originate from the
activity of multiple classes of channels with different pharmacological
sensitivities and unique functional properties. Neuronal CaV channels
are implicated in a variety of neurological and psychiatric diseases
including epilepsy, Parkinson's disease, chronic pain, schizophreniam channels.
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pscombe).
l rights reserved.and bipolar disorder [1–9]. Relatively large differences in the
voltage-dependence of channel activation between CaV3 (T-type)
channels on the one hand, and CaV1 (L-type) and CaV2 (N, P/Q,
R-types) channels on the other offered the ﬁrst clues that many
cells expressed more than one type of voltage-gated calcium channel
[10–12]. Genome and transcriptome sequencing showed that
mammalian neurons can express up to 9 of 10 different CaV α1
subunit genes [13,14]. Low threshold activation and slow deactiva-
tion characteristics are features of all CaV3 channels that set them
apart from CaV1 and CaV2 family members [15].
With the exception of the skeletal muscle CaV1.1 that functions
primarily as a voltage sensor, the unifying function of CaV channels is
1523D. Lipscombe et al. / Biochimica et Biophysica Acta 1828 (2013) 1522–1529rapid control of voltage-dependent calcium entry [16,17]. Calcium
entering through different CaV channels activates distinct signaling
pathways depending on the unique sub-cellular localization, protein
associations, and functional properties of CaV channels [13]. Thus,
certain CaV channels are commonly associated with certain cellular
functions, but new roles for CaV channels continue to be discovered.
CaV1 channels expressed in neurons (encoded by Cacna1c, Cacna1d,
and Cacna1f genes) support a range of calcium-dependent processes
including modulation of gene expression, long and short-term changes
in synaptic plasticity (CaV1.2, CaV1.3) [18–20], transmitter release at
sensory nerve terminals (CaV1.3, CaV1.4) [21,22], and intrinsic spiking
(CaV1.3) [23]. CaV2 channels (encoded by Cacna1a, Cacna1b, and
Cacna1e genes) are primarily located at presynaptic nerve terminals
where they control voltage-dependent calcium entry that triggers
transmitter release [24,25]. CaV3 channels (Cacna1g, Cacna1h, Cacna1i
genes) underlie pacemaking in many neurons including thalamic
relay neurons [4,26].
This review is focused on the even ﬁner granulation of structural
and functional diversity among CaV channels that originates from
each major CaV channel gene. Distinct CaV channels expressed in a
given cell, distinguished by relatively small discrete differences in
amino acid sequence, may number in the tens to hundreds depending
on the extent of alternative pre-mRNA splicing [15,27]. Several sites
of alternative splicing are present in Cacna1 genes predicting varia-
tions in amino acid sequence (e.g. see Fig. 1 for Cacna1b). Assuming
each exon is regulated independent of the others, the number of dis-
crete mRNA isoforms possible from each Cacna1 gene is potentially
staggering (2N for N sites of alternative splicing). Analyses of different
brain regions at different stages of development show that the
composition of the pool of CaV mRNA splice isoforms varies with
cell-type, state of development, and possibly neuronal activity
[15,28]. This suggests that anticipated subtle functional differences
among splice isoforms within a given CaV family are either individu-
ally or collectively contributing in important ways to neuronal
processes. Pre-mRNA splicing is also implicated in many neurological1
18a, 24a or 31a
Cassette exons
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Fig. 1. Alternatively spliced exons in Cacna1b and patterns of expression. Cacna1b pre-mRN
proteins in neurons. Alternatively spliced exons e18a, e24a, and e31a are cassette exons. E
in different regions of the nervous system, in different types of cells, and at different sta
shown for embryonic and adult brain, superior cervical ganglia (SCG), cortex, and nociceptor
properties have been described in a series of publications [15,28,85,86,88,119,120].diseases. Disease-causing mutations can disrupt splicing such as
inherited frontotemporal dementia and Parkinsonism linked to
chromosome 17, amyotrophic lateral sclerosis, spinocerebellar ataxia
8, and myotonic dystrophy [29]. Alternative splicing can play a role in
modifying disease such as in the case of Timothy syndrome [30]. The
cellular and behavioral consequences of only a few CaV splice
isoforms are known (discussed below), but this should change as
new methods are developed.
1.1. Alternative pre-mRNA splicing
Alternative pre-mRNA splicing is particularly prevalent in themam-
malian brain [31,32], consistentwith the theory that alternative splicing
evolved in parallel with biological complexity [33]. Alternative splicing
is essential for normal neuronal development, axon targeting, neuronal
excitability, and neural circuit formation [27,34–38]. Several excellent
reviews outline the molecular interactions involved in alternative
pre-mRNA splicing [39–42]. In brief, this form of pre-mRNA processing
occurs in the cell's nucleus and it is controlled by the concerted actions
of cell-speciﬁc splicing factors (SFs). These cell-speciﬁc SFs bind to
consensus motifs on pre-mRNAs and inﬂuence the action of the
spliceosome by promoting or repressing inclusion of alternatively
spliced exons, and promoting or repressing the use of alternative splice
acceptor or donor sites at intron/exon boundaries. The cell-speciﬁc fea-
tures of alternative pre-mRNA splicing are controlled by the collective
action of cell-speciﬁc SFs that bind to elements encoded in each gene
[40,43–49].
SFs known to control alternative pre-mRNA splicing in neurons in-
clude Nova1/2 [45], nPTB [50–52], rbFox1/2/3 [53–55] and SF2/AF
[56]. Networks of genes targeted by speciﬁc SFs have been generated
from genome-wide analyses of pre-mRNAs that bind them. Based on
data from these types of studies, certain SFs are shown to associate
with genes that control particular aspects of neuronal function. For
example, Nova appears to preferentially regulate alternative splicing
of pre-mRNAs encoding proteins found at inhibitory synapses4618a 24a 31a 37a /37b
37a 37b
Mutually exclusive exons
Nociceptors Nociceptors
All neurons
A undergoes extensive alternative splicing generating 10 s to 100 s of unique CaV2.2
37a and e37b are mutually exclusive exons. Alternatively spliced exons are expressed
ges of development. Examples of different expression patterns of splice isoforms are
s. The tissue distribution and functional consequences of these exons on CaV2.2 channel
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of CaV pre-mRNAs is summarized below.
1.2. Alternative splicing and voltage-gated calcium channels
The large number of CaV channel splice isoforms expressed in the
nervous system, combined with their distinct expression patterns
according to region and cell type, is consistent with the remarkable
range of neuronal functions and behaviors regulated by CaV channels.
Experiments aimed at establishing the contributions of CaV channel
splice isoforms to neuronal function have been hindered by the lack of
isoform-speciﬁc tools to tease their contributions apart at the protein
level. Nonetheless, experimental approaches that selectively target
mRNA splice isoforms and that directly modify alternatively spliced
exons at the gene level have proven valuable. Similarly, knowledge of
cell-speciﬁc expression patterns of splice isoform mRNAs gives impor-
tant clues about function (see below).
Sites of alternative splicing in Cacna1 genes are typically, although
not exclusively, located in regions encoding hyper-variable domains of
CaV proteins that presumably can accommodate changes in protein
structures. These include the intracellular C-termini and the II–III
intracellular linker (see Fig. 1 and see [59]). The location of certain
alternatively spliced exons is conserved among Cacna1 genes. For
example, all but one Cacna1 gene contain an alternatively spliced
exon that encodes a peptide in the putative extracellular linker
between transmembrane spanning helices S3 and S4 in domain IV of
CaV channels. In some genes such as Cacna1a and Cacna1b, a homolo-
gous alternatively spliced exon also encodes a short peptide sequence
in the S3–S4 linker of domain III [58,60,61]. The composition and/or
length of the S3–S4 extracellular linker exons inﬂuences voltage-
dependent gating of CaV channels, perhaps unsurprisingly given their
proximity to putative S4 voltage-sensors [62,63] (Fig. 2). The modula-
tion of CaV channel activation induced by these exons can be relatively
small (5–7 mV) but such changes can signiﬁcantly impact the total
movement of calcium during action potential-like stimuli [62]. Thus,Test Potential (mV)
I/Imax I/Imax
1
0-90 60
0
3030-60
3.1 1.3 1.2 2.2 1.1Ca V
1
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Fig. 2. The potential impact of alternative splicing of CaV channels on the voltage range over
V1/2 and k values from the literature from recordings using 1–2 mM calcium as charge carri
(V1/2=6.2 mV, k=5.3 mV; [121]), CaV1.2 (V1/2=−17 mV, k=8 mV; [122]), CaV1.3 (V1/
CaV3.1 (CaV3.1, V1/2=−46 mV, k=4.11; [126]). B, Alternative splicing of exons can modif
for each CaV channel family. Approximate locations of regions encoded by alternatively s
CaV2.2 data are from [125]; CaV1.1 data are from [64]; and CaV3.1 data are from [127]. CaV1.2
pared using 11 mM barium as charge carrier, this will shift the voltage-dependence of activa
an approximate operating range for CaV1.2 and CaV1.3 (dotted lines) based on the differen
obtained with 2 mM Ca.different CaV splice isoformsmight be selected to ﬁne-tune the coupling
efﬁcacy between membrane depolarization and calcium entry
according to cell needs (Fig. 2). CaV1.1 channel splice isoforms with dif-
ferent IVS3–IVS4 linkers are also expressed in the skeletal muscle and
these originate from different mRNAs that either contain or lack exon
29 of Cacna1s. The major form of CaV1.1 early in muscle development
lacks e29, but it is included with greater frequency during pre-mRNA
splicing with maturation [64]. CaV1.1 splice isoforms lacking e29a gen-
erate larger currents that activate at more negative voltages compared
to clones that contain e29a [64].
Regardless of their location relative to the voltage sensors and
putative gating domains, many alternatively spliced Cacna1 exons
impact CaV channel gating. For example, alternatively spliced cassette
exons encoding peptide sequences and the use of alternative splice
junctions in intracellular regions of CaV2.2, CaV1.2, and CaV1.3 channels
inﬂuence the voltage dependence of channel activation and inactiva-
tion, channel gating kinetics, and calcium-dependent inactivation
[65–69]. The different C-termini splice isoforms of CaV1.3 channels
have distinct tissue distributions with a short C-terminus isoform de-
void of tonic inhibitory control exerted by full length C-termini [68].
This short C-terminus isoform is expressed in the brain but not in the
heart and passes substantially more current during short burst action
potential-like stimuli [68].
1.3. Cell-speciﬁc factors that control alternative splicing of exons of
Cacna1 genes
Comparative analyses of CaV mRNAs expressed in different regions
of the nervous system provide strong evidence of cell-speciﬁc and
development-speciﬁc splicing events [15,27,28,70–72]. Splicing fac-
tors bind their unique motifs which are often located in introns that
ﬂank target AS exons, but these motifs can also exist within the target
exon itself [73]. SF binding location relative to the target exon is often
predictive of the overall impact of the SF. For example, Nova and
rbFox proteins typically repress exon inclusion when they bind theirTest Potential (mV)
3.1 1.3 1.2 2.2 1.1aV
-90 0 603030-60 90
licing
B
which each channel subtype can operate. Boltzmann activation curves are plotted using
er, except for data for CaV1.1 obtained from recordings using 10 mM calcium. A, CaV1.1
2=−36 mV, k=8 mV; [123,124]), CaV2.2 (V1/2=−0.1 mV, k=7.5 mV; [125]), and
y voltage-dependence of activation and this will increase the operating voltage range
pliced exons that inﬂuence the voltage-dependence of channel activation are shown.
[128] and CaV1.3 [67,129] isoforms that have different activation properties were com-
tion relative to recordings with 2 mM Ca. For comparison with other data, we illustrate
t V1/2 values from [67,128,129] but with reference to the activation curves shown in A
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typically promote exon inclusion when they bind downstream of
the target exon [74,75]. The coordinated expression and/or activity
of available SFs determines the composition of the pool of CaV
channel isoforms in a given cell type [27]. Splicing factors are in
turn regulated by cell-speciﬁc molecules including miRNAs [76], ki-
nases, and phosphatases [77,78]. The potential exists to approximate
which CaV mRNA isoforms are expressed when, and in which
cell-type, based on SF binding sites. Cacna1-derived sequences are
present in recent genome-wide, high throughout sequence analyses
of the sites of splicing factor binding, and certain SF binding sites
have been functionally validated. For example Nova-2, a brain-
speciﬁc splicing factor, binds Cacna1b and Cacna1a pre-mRNAs to
promote inclusion of e24a and repression of e31a thereby inﬂuencing
the composition of both CaV2.1 and CaV2.2 mRNAs [58,60]. E24a and
e31a encode short peptide sequences in the IIIS3–IIIS4 and IVS3–IVS4
linkers, respectively, and as discussed above, they modulate the
voltage-dependence of CaV2 channel activation (Fig. 2). RbFox
proteins, a family of splicing factors implicated in the control of alter-
native splicing during development, were recently shown to repress
e9* and promote inclusion of e33 of Cacna1c, inﬂuencing the compo-
sition of CaV1.2 mRNAs expressed in the cortex [79,80]. At a different
splice site, polypyrimidine tract-binding protein (PTB) and its neuro-
nal homolog (nPTB) control the developmental switch from exon 8 to
exon 8a-containing CaV1.2 mRNAs in neurons [81]. Many more
cell-speciﬁc splicing events involving CaV pre-mRNAs are described
for which the corresponding SFs have not yet been identiﬁed.
Identifying these SFs is necessary to understand how cells control
CaV calcium signaling.1.4. Mutually exclusive splicing
The alternatively spliced exons that encode short peptide
sequences in the S3–S4 linkers of CaV channels are cassette exons,
they are either included or excluded during pre-mRNA processing.
In either form, exon included or skipped, the reading frames of the re-
sultant mRNAs are typically preserved and translated into functional
CaV isoforms. An exception to this involves cassette exons that shift
the reading frame, when included or when excluded, leading to
non-functional proteins. This form of alternative splicing regulates
expression levels of critical proteins, including SFs, and is known to
be critical for early cellular differentiation [82]. By contrast, mutually
exclusive splicing involves the selection of one of a pair of exons that
encode slightly different sequences. In mutually exclusive splicing,
the mechanism of exon selection must incorporate a form of steric
hindrance to ensure exon selection is strictly mutually exclusive. If
neither one of the pair of mutually exclusive exons e37a and e37b
of Cacna1b is included during pre-mRNA splicing, this results in aBrain
Nociceptors
Wild-type e37a – e37b Mutant e
Fig. 3. Theoretical model showing how the action of splicing factors might regulate the expre
sequence in CaV2.2 pre-mRNA preventing its inclusion during alternative pre-mRNA splicing
other neurons that express e37a. In the absence of the splicing repressor, e37a and e37b ar
published in [86]. When e37a is moved to the e37b position, e37a is repressed consistent
e37a position, it is expressed at wild-type levels inconsistent with the presence of a represframe shift which creates an early stop and a non-functional truncat-
ed CaV protein [66]. The same is true for the homologous exons e37a
and e37b of Cacna1a [83,84] and e8 and e8a of Cacna1c [81]. Thus,
aberrant splicing involving mutually exclusive exons is expected to
be deleterious resulting in non-functional protein.
The splicing factors that regulate mutually exclusive splicing of
e37a and e37b of Cacna1b and Cacna1a are not known. E37a of
Cacna1b is expressed in a limited number of cell types including
nociceptors, whereas 37b is abundant throughout the nervous system
[28,85]. Several mechanisms could explain the observed cell-speciﬁc
expression pattern but all involve cell-speciﬁc splicing factors. Based
on our analyses of CaV2.2 mRNAs expressed in dorsal root ganglia
and brain of mice that contain either tandem e37a or tandem e37b
exons, we favor a mechanism involving a splicing repressor that
binds to e37a [86]. We predict this putative splicing repressor is
expressed in most neurons but is absent or at low levels in
nociceptors and other neurons that express e37a-contaiing CaV2.2
mRNAs (Fig. 3).1.5. Functional consequences of alternative splicing
Alternatively spliced exons are present in >95% of multi-exon
genes [87] arguing that cellular control over exon selection must
play a critical role in normal development and cell function [43]. By
deﬁnition, cell-speciﬁc splicing events occur in a limited population
of cells and tissues making it difﬁcult to locate the products and,
most of the time, tools such as antibodies and modulators to
selectively identify and speciﬁcally control the activity of individual
splice isoforms do not exist. The enrichment of the mutually exclusive
e37a of Cacna1b in capsaicin-responsive nociceptors of dorsal root
ganglia therefore offered a unique opportunity to assess its functional im-
portance. Several other features of this system, as well as knowledge of
the functional differences between e37a and e37b CaV2.2 splice isoforms,
were advantageous. Among these features are: 1) Ameasurable behavior
that is relatively easy to isolate and characterize; nociceptors have a
well-deﬁned role in detection of thermal stimuli and standard methods
exist to monitor thermal responsiveness in vivo. 2) CaV2.2 channels
dominate in controlling calcium entry to trigger glutamate release from
presynaptic terminals of nociceptors in the spinal dorsal horn. 3) Several
neurotransmitters and drugs down regulate synaptic transmission by
inhibiting the gating of presynaptic CaV2.2 channels at nociceptor
terminals through G protein coupled receptor activation. 4) E37a
promotes Gi/o protein coupled receptor inhibition of CaV2.2 by a mech-
anism that persists independent of the stimulus. This pathway contrasts
with Gi/o protein coupled receptor inhibition of e37b CaV2.2 channel
isoforms that is reversed by membrane depolarization. Two comple-
mentary approaches were used to assess the functional importance of
e37a in vivo [88].37a – e37a Mutant e37b – e37b 
ssion of e37a in different neurons. A putative splicing repressor (orange) binds to e37a
. The putative splicing repressor is expressed in most neurons except in nociceptors and
e equally likely to be included during pre-mRNA splicing. The model is based on data
with the presence of an exonic repressor element [86]. When e37b is moved to the
sor element that resides exclusively in the intron [86].
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Without tools to selectively inhibit e37a-CaV2.2 and to leave
e37b-CaV2.2 channels unaffected, isoform-speciﬁc siRNAs were used
to reducemRNA levels and protein levels in vivo [88]. Behavior analyses
of thermal and mechanical thresholds in mice, following intrathecal
application of isoform-selective siRNAs, suggested that e37a-CaV2.2
channels preferentially participate in the transmission of basal thermal
nociception. E37a-CaV2.2 channels also mediated thermal hyperalgesia
that accompanied peripheral nerve injury based on the complete
reversal of thermal withdrawal thresholds inmice injectedwith siRNAs
targeting e37a-CaV2.2mRNAs [88]. This study showed that e37a-CaV2.2
splice isoforms are targeted to nociceptors nerve terminals and that
they have a preferred role in mediating synaptic transmission in
thermosensing.
An alternative experimental strategy was needed to establish if
functional differences in Gi/o protein inhibition between e37 CaV2.2
splice isoforms impact behavior. In order to do this, e37a in the
mouse Cacna1b gene was replaced with a second copy of e37b pre-
serving wild-type CaV2.2 levels [86]. No obvious behavioral deﬁcits
were observed in e37a-null mice and withdrawal reaction times to
thermal stimuli were not different from wild-type mice. However,
in mice lacking e37a spinal morphine was a less effective analgesic
to thermal stimuli compared to wild-type mice. This report offers ev-
idence that disrupting an individual splicing event can impact animal
behavior in subtle but measurable ways, in this case by altering the
pharmacological efﬁcacy of morphine as an analgesic [86].
1.7. Alternative pre-mRNA splicing, calcium channels, disease, and
therapeutics
The most widely cited example of alternative splicing involves a
gene critical in sex determination pathways in the fruit ﬂy Drosophila
melanogaster [89,90]. The splicing factor transformer (tra) controls al-
ternative splicing of doublesex (dsx), the master controller of somatic
sexual dimorphism in ﬂies [91,92]. The consequences of aberrant
splicing in the sex determination pathway are dramatic and global
[93]; however, the majority of alternative pre-mRNA splicing events
likely participate in delimited cellular processes.
Assessing the impact of such events on animal behavior, while more
challenging, is potentially very relevant to processes that could contrib-
ute to neurological and psychiatric diseases [35,94–98]. In some cases
altered splicing patterns for a particular gene or a subset of genes ex-
plain the pathophysiological manifestations of a disease such as cystic
ﬁbrosis [99,100]. In these cases, the presence of certain alternatively
spliced mRNAs and proteins serves as disease biomarkers and, in the
case of certain cancers, the presence of speciﬁc isoforms of MDM2,
survivin-2B and CD44 deﬁnes cancer type [101]. In a very recent
study, the loss of the splicing factor muscleblind-like protein 2
(Mbnl2) disrupts normal splicing of hundreds of exons and produces
neurological symptoms similar to those that characterize human
myotonic dystrophy [102]. Exon 12a of Cacna1d is among the list of
affected splicing events in mice lacking Mbnl2 and, altered levels of
e12a-containing CaV1.2 mRNAs are also observed in brains of human
patients with myotonic dystrophy [102]. In humans, myotonic dystro-
phy is associated with abnormal CUG expansions in RNAs. A hypothesis
presented in this study posits that CUG repeats sequester Mbln2, inter-
fering with target exon splicing, and generating abnormal patterns of
splice isoforms, including CaV1.2 mRNAs, in the nervous system.
In other cases, alternative splicing acts as a disease modiﬁer. For
example, mutually exclusive alternatively spliced exons e8 and e8a of
human CACNA1C are mutated in two different types of Timothy's syn-
drome respectively [30]. Because these exons are mutually exclusive,
the effect of a gain-of-functionmutation in one exonmight bemitigated
to some degree by the activity of the alternativewild-type exon in some
tissues [30]. One of a pair of mutually exclusive exons, e8B, in CACNA1Dis mutated in the human disorder SANDD syndrome and is associated
with deafness and bradycardia [103]. Interestingly, the exons affected
in both Timothy syndrome and SANDD map to homologous regions of
CACNA1C and CACNA1D genes and encode homologous regions of
CaV1.2 and CaV1.3 channels, respectively. Changes in the relative abun-
dance of CaV1.2 channel splice isoforms have also been documented
during cardiac disease [104]. Finally, spinocerebellar ataxia type 6
(SCA6) is associated with poly-glutamine repeats in the C-terminus of
CaV2.1. The choice of an alternative 3′ acceptor during pre-mRNA splic-
ing determines whether e47 of CACNA1A is in frame or out of frame
resulting in an early stop and a truncated C-terminus. In patients with
SCA6, inclusion of the complete e47 during splicing leads to CaV2.1
mRNAs containing expanded CAG repeats; the translation of these
mRNAs generates CaV2.1 channels with poly-glutamine repeats that
are responsible for the severity of SCA6 [65,105,106].
The role of alternative pre-mRNA splicing of CaV channels in disease,
particularly as a disease modiﬁer, adds credence to therapeutic
strategies designed to target splicing factors [107–109] and speciﬁc
splice isoforms [110,111]. For example, in Timothy's syndrome, it
might be possible to shift the balance of splicing toward the
non-mutated exon by targeting the splicing factors that control exon
selection or by knocking down the mutated splice isoforms that
underlie the gain of function phenotype [30]. Isoform-speciﬁc antisense
oligonucleotides and interference RNAs have been developed to knock-
down mutated mRNA isoforms as a strategy to treat certain types
of thalassemias and dystrophies, cystic ﬁbrosis, cancer, and pain
[88,112–115]. Other approaches to modify splicing events involve the
use of bifunctional oligonucleotides. These hybrid molecules are
designed to bind to speciﬁc regions of pre-mRNAs and to modify
splicing via an antisense-targeting domain. For example, bifunctional
oligonucleotides have been used to enhance e7 inclusion in SMN2 to
reduce the severity of spinal muscular atrophy [116–118].2. Concluding remarks
Cell-speciﬁc control of alternative pre-mRNA splicing is used
to optimize depolarization-dependent calcium signaling in different
parts of the nervous system, at different stages of development,
and potentially depending on neuronal activity. Comparing unique
functional characteristics among splice isoforms points to domains on
CaV channels that regulate function. Identiﬁcation of the cell-speciﬁc
splicing factors that determine the composition of CaV splice isoforms
is nowneeded. This informationwill be valuable not only to understand
the coordinated expression of CaV splice isoforms and their relationship
to other functionally related genes, but also to develop strategies to
manipulate splicing patterns. The role that alternative splicing plays in
disease particularly as a diseasemodiﬁer suggests novel therapeutic ap-
proaches based on selectively down regulating disease causing isoforms
and up-regulating isoforms that have therapeutic beneﬁts. Continued
technical advances in transcriptome analyses according to cell-type
will greatly assist in identifying functionally relevant CaV channel splice
isoforms, and ultimately their behavioral signiﬁcance.Acknowledgements
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